Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will report its fourth quarter and year-end 2022 financial results on March 27, 2023. The company is focused on developing ACU193, a novel therapeutic targeting soluble amyloid beta oligomers for Alzheimer’s disease treatment. A conference call and live audio webcast will occur at 8:00 a.m. ET for a business and financial update. This important milestone is part of Acumen's efforts in advancing its investigational product candidate, which is currently in a Phase 1 clinical trial.
- None.
- None.
CHARLOTTESVILLE, Va. and CARMEL, Ind., March 20, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2022 financial results on Monday, March 27, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When will Acumen Pharmaceuticals report its 2022 financial results?
What is the focus of Acumen Pharmaceuticals?
What is ACU193?
What time is the conference call for Acumen Pharmaceuticals?
Where can I listen to the Acumen Pharmaceuticals conference call?
